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Autosomal dominant polycystic kidney disease (ADPKD) is a common, genetically determined developmental disorder of the kidney that is
characterized by cystic expansion of renal tubules and is caused by truncating mutations and haplo-insufficiency of the PKD1 gene. Several
defects in cAMP-mediated proliferation and ion secretion have been detected in ADPKD cyst-lining epithelia. Unlike the ubiquitous PKA, the
cAMP-dependent CREB-kinase, Protein Kinase X (PRKX) is developmentally regulated, tissue restricted and induces renal epithelial cell
migration, and tubulogenesis in vitro as well as branching morphogenesis of ureteric bud in developing kidneys. The possibility of functional
interactions between PKD1-encoded polycystin-1 and PRKX was suggested by the renal co-distribution of PRKX and polycystin-1 and the
binding and phosphorylation of the C-terminal of polycystin-1 by PRKX at S4166 in vitro. Early consequences of PKD1 mutation include
increased tubule epithelial cell–matrix adhesion, decreased migration, reduced ureteric bud branching and aberrant renal tubule dilation. To
determine whether PRKX might counteract the adverse effects of PKD1 mutation, human ADPKD epithelial cell lines were transfected with
constitutively active PRKX and shown to rescue characteristic adhesion and migration defects. In addition, the co-injection of constitutively active
PRKX with inhibitory pMyr-EGFP-PKD1 into the ureteric buds of mouse embryonic kidneys in organ culture resulted in restoration of normal
branching morphogenesis without cystic tubular dilations. These results suggest that PRKX can restore normal function to PKD1-deficient
kidneys and have implications for the development of preventative therapy for ADPKD.
© 2007 Published by Elsevier B.V.Keywords: Cyclic AMP; Renal cystic disease; Developmental biology; Adhesion; Migration; Differentiation; Morphogenesis1. Introduction
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
is a leading cause of endstage renal failure and affects 500,000
patients in USA [1]. At present, there is no proven therapy and
50% of individuals who inherit mutations in the PKD1 gene will
require hemodialysis or renal transplantation. PKD1 encodes a
membrane protein, polycystin-1 [2], the intracellular C-terminal
domain of which has specific tyrosine and serine sites for phos-
phorylation by c-src, focal adhesion kinase and protein kinase A
(PKA) as well as an RRSSR consensus sequence for putative
S4166 phosphorylation [3,4,21,39,40]. Polycystin-1 is highly
expressed in developing kidneys, but significantly less ex-⁎ Corresponding author. Tel.: +1 212 659 9383; fax: +1 212 849 2434.
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doi:10.1016/j.bbadis.2007.09.003pressed in normal adult kidneys [5–7]. Depending on cell dif-
ferentiation state and developmental stage, polycystin-1 has
been localized on basal, lateral and apical plasma membranes
where it forms large multi-protein complexes with cell–matrix
focal adhesions, cell–cell adhesion complexes and primary cilia,
respectively [6,8]. Inactivation of PKD1 results in increased
adhesion of renal epithelia to collagen matrix, decreased mi-
gration in response to growth factors, stunted branching mor-
phogenesis and cystic dilations of the terminal branches and tips
of the ureteric bud [9]. Direct functional studies have shown that
inhibition of PKD1-encoded polycystin-1 leads to cystic mal-
development of mouse kidneys and suggests a critical role for
normal polycystin-1 in the differentiation and controlled mor-
phogenesis of the kidney by regulation of tubular diameters
[9,10]. Functional decline in ADPKD patients is due to pro-
gressive renal cystic enlargement and typically does not result in
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expansion arises early in development where it appears to be
initiated in the ureteric bud/collecting tubules, this presents a
long window of opportunity to develop effective retardation and
preventative therapies [11,12].
Several abnormalities in response to cAMP have been docu-
mented in ADPKD, including increased cAMP-dependent proli-
feration, increasedATP release, and alterations in secreted ion and
fluid transport [13–17]. In addition to the ubiquitously expressed
PKA, cAMP-mediated responses can be mediated via Protein
Kinase X (PRKX), a serine/threonine kinase gene on the X
chromosome (Xp22.3) [31,32]. Functional differences between
PRKX and PKA have been reported [18] including a PRKX-
specific role in granulocyte/macrophage lineage differentiation
[33]. Previously we have shown that similar to PKA, cAMP
induces translocation of PRKX to the nucleus of renal epithelial
cells and activates CRE-promoter elements [3]. Unlike PKA,
however, PRKX belongs to an ancient subfamily containing Dic-
tyostelium KAPC-DICDI, and consists of a single catalytic and a
single regulatory subunit [3,34,35]. PRKX activation results in
the stimulation of cell migration and tubulogenesis in renal
epithelial cells [3] and its overexpression in embryonic mouse
kidneys in organ culture activates ureteric bud branching mor-
phogenesis [36], suggesting a role for PRKX in regulation of
tubulogenesis during kidney development.
The current studies sought to determine whether PRKX was
able to interact with polycystin-1 in renal epithelia and to evaluate
its potential role in the restoration of normal renal epithelial
function, morphogenesis and tubule diameter control in PKD1-
deficient kidneys.
2. Materials and methods
2.1. Construction of PRKX expression vectors
The generation of recombinant peGFP/PRKX, pFLAG/PRKX constructs
has been described previously [3]. A constitutively active peGFP/PRKX.ca
construct was engineered by point mutagenesis (His 93 changed to Gln and Trp
202 to Arg) as described for PKA kinase [27]. This construct causes activation
of kinase activity and nuclear translocation in the absence of added cAMP [20].
For ureteric bud microinjection and long-term epithelial cell transduction, viral
PRKX-expressing constructs were generated using self-inactivating lentiviral
(VVC) vectors [37]. peGFP-PRKX and peGFP/PRKX.ca fusion proteins were
excised with XhoI and BamHI and ligated with VVC vectors under the control
of the CMVearly promoter, to generate VVC-peGFP/PRKX and VVC-peGFP/
PRKX.ca as described previously [36].
2.2. Construction of PKD-1-CTD expression vectors
Human PKD1-C-terminal domain (CTD) fusion protein was prepared for
Escherichia coli expression by PCR of a 0.6 kb DNA fragment encoding amino
acids 4105–4303 and subcloned into pET30 LIC (Novagen) vector which encodes
in frame N-terminal His- and S-tags, as previously described [4]. For mammalian
expression and transfection analysis, the previously described pMyrEGFP-PKD1-
CTD expression plasmid was used, [4,29] and for ureteric budmicroinjections and
long-term expression VVC-Myr-EGFP-PKD1-CTD was used [3,9].
2.3. Cell culture
Temperature-sensitive (ts), conditionally immortalized human renal epithe-
lial cells derived from microdissected normal human fetal collecting tubule(HFCT), normal human adult collecting tubule (NHCT) and ADPKD cyst lining
epithelia (with a germline mutation truncating the polycystin-1 protein at amino
acid 3078) were grown according to our standard protocols [19,30]. To attain
full differentiation, cells were grown to 70% confluence at 33 °C, and then
transferred to the non-permissive temperature of 37 °C for 5–10 days prior to
use. JAR human choriocarcinoma cells (ATCC) were cultured in RPMI 1640
(Life Technologies, Inc.) with 10% FBS and MDCK cells were grown in
Dulbecco's Modified Eagles Medium (DMEM) plus 10%. FBS.
2.4. In situ hybridization
Deparaffinized, dehydrated kidney sections were treated with proteinase K,
prehybridized with triethanolamine/acetic anhydride, and hybridized overnight
with digoxigenin-substituted PRKX-antisense or sense probes. After washing in
0.1× SSC (0.15 M sodium chloride/0.015 M sodium citrate, pH 7.0), sections
were incubated in anti-digoxigenin antibody/alkaline phosphatase and color
developed with Nitro Blue Tetrazolium (NBT) reagent (Roche Molecular
Biochemicals).
2.5. Northern blot analysis
Total RNAwas fractionated on agarose/formaldehyde gels and the integrity
of RNA monitored with ethidium bromide prior to transfer to GeneScreen
membranes using 25 mM sodium phosphate pH 6.5. Filters were prehybridized
overnight at 42 °C in 50% formamide, 0.04% PVP, 0.04% BSA, 0.04% Ficoll,
1% SDS, 0.75 M NaCl, 0.075 M sodium citrate and denatured salmon sperm
DNA (100 mg/ml). Hybridization with PRKX and 14S RNA 32P-labeled cDNA
probes was carried out in 0.02% PVP, 0.02% BSA, 0.02% Ficoll at 42 °C for
24 h followed by 4 washes: 2× SSC, 0.1% SDS, 15 min, 65 °C; 1× SSC, 0.1%
SDS, 15 min, 65 °C; 0.5× SSC, 0.1% SDS, 15 min, 65 °C; 0.1× SSC, 0.1% SDS,
15 min, 65 °C. RNA bands were visualized by autoradiography.
2.6. Phosphorylation studies
Polycystin-1 was immunoprecipitated from HFCT cell lysates using a fully
characterized mono-specific anti-human polycystin-1 C terminal antibody [25]
and agarose beads, and then incubated for 45 min at 37 °C with kinase buffer
(10 mM HEPES, 3 mM MnCl2, pH 7.3) containing affinity purified pFLAG-
PRKX fusion protein and 10 μCi α-32P-ATP. The beads were washed 3 times
with kinase buffer and 15 ml TBS containing 50 mM EDTA and 4 ml of 5×
Ramini sample buffer. After heating for 5 min at 95 °C, phosphorylated proteins
were resolved by SDS-PAGE [41] followed by autoradiography. In addition,
His/FLAG/PKD1-CTD or 4166/4252 truncated mutant fusion proteins made in
E. coli and purified using a nickel column were incubated with pFLAG-PRKX
fusion protein immunoprecipitated from JAR cell lysates using anti-FLAG
beads and phosphorylation determined using 32γ-ATP as described above.
Studies were conducted in the presence or absence of 8-Br-cAMP (100 μM) or
H89 inhibitor (10 μM).
2.7. Co-immunoprecipitation of PRKX and polycystin-1
HFCT cell lysates (800 μg) were immunoprecipitated with 10 μl anti-PRKX
antibody (Biocompare) and 25 μl A/G beads at room temperature for 2 h. After
extensive washing, aliquots were fractionated on 5% SDS/PAGE and im-
munoblotted with anti-PRKX (1:500) and anti-polycystin-1 (1:10,000). Lysate
immunoprecipitated with beads only acted as negative control.
2.8. Cell adhesion assays
ADPKD cells were transfected with peGFP/PRKX or peGFP/PRKX.ca
using Lipofectamine 2000 (Invitrogen), washed and cultured for 24 h prior to
Fluorescence-Activated Cell Sorting (FACS) to isolate GFP positive cells. 2000
GFP+ or control non-transfected cells were plated per well in 96 well tissue
culture plates precoated with type I collagen. After 4 h of attachment, unattached
cells were removed by aspiration and adherent cells quantitated by the
colorimetric aqueous MTS assay (Cell Titer 96TM Aq., Promega).
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ADPKD cells were transfected with peGFP/PRKX using Lipofectamine
2000 (Invitrogen), washed and cultured for 24 h prior to FACS sorting. GFP+ or
control untransfected cells were washed with serum-free medium and labeled
with fluorescent calcein-AM (Molecular Probes). 2000 labeled cells treated with
or without 100 μM 8-Br-cAMP or 10 μM H89 were plated in 0.8 ml DMEM+
1% FBS in triplicate into 24 well chambers adapted for the Fluoroblock (Falcon)
apparatus. After 4 h, 5% FBS was added to the lower chamber medium to
establish a 1–5% serum gradient and migration of cells from the upper to lower
chamber quantitated at 4–48 h using a microfluorimetric plate reader (HTS
7000, Perkin Elmer Cetus).
2.10. Tubulogenesis assay in 3-dimensional collagen gels
FACS-sorted MDCK cells, with or without transfection of peGFP/PRKX,
peGFP/PKD1-CTD or peGFP/PKD1.tm (PKD1 truncated mutants), were
washed, grown for 24 h, washed three times in serum-free medium and 500
cells plated per well (12-well format) in collagen type I gels: 1 vol. 10× MEM, 1
vol sodium bicarbonate (42 mg/ml), 1/2 vol FBS, 3 vol type I collagen, 4.5 vol
sterile water. After 10 days of culture in DMEM+10% FBS, gels were fixed in
ice-cold methanol and stained with rhodamine–phalloidin for 8 h prior to
examination by fluorescence microscopy.Fig. 1. (A) Northern blot analysis of PRKXmRNA expression in human kidneys. Hum
gels and transferred to a nitrocellulose membrane. The membrane was then prehybrid
further detail). FK: normal human fetal kidney, 16 weeks gestation. AK: normal huma
arrowhead indicates 14S ribosomal RNA control. (B) PRKX and PKD1 mRNA ex
antisense PRKX (A–C) or sense PRKX (G) or PKD1 (D–F) fragment riboprobes
alkaline phosphatase immunohistochemistry (please see Materials and methods for fu
Normal human adult kidney. (C and F) ADPKD cystic kidney. (G) PRKX sense pro2.11. Mouse embryonic kidney organ culture and viral
vector microinjection
Embryonic day (E) 11–12 kidney pairs were dissected from timed pregnant
CD-1 mice (Charles Rivers) using a stereomicroscope (Olympus) with a Scion
imaging system. Kidneys were cultured on 24 mm Transwell Clear membrane
inserts for 3–5 days and media changed daily [28,36]. On day 0, 20–200 nl (1–
4×107 TU/ml); VVC-peGFP/PRKX.ca; VVC-pMyr-EGFP-PKD1-CTD; VVC-
peGFP/PRKX.ca plus VVC-pMyr-EGFP-PKD1-CTD; VVC vector alone; or
PBS (sham control) were microinjected into the ureteric bud lumen using sterile
transfer tips (15 mm internal diameter), a micromanipulator and transjector
(Eppendorf) and comparisons made with uninjected kidneys. After 3–5 days of
organ culture, kidney explants were fixed in ice-cold methanol for 15 min. prior
to immunofluorescent staining with anti-calbindin and anti-WT-1 antibodies as
described previously [36].
2.12. Microscopy and morphometric data analysis
Morphological changes were documented daily using the Olympus/Scion
system. Immunofluorescence imaging was carried out by laser-scanning confocal
microscopy (BioRad Radiance, MSSM core facilities) and Image J (NIH), an open
domain Java image processing system, was used to calculate area and pixel value
statistics, to measure distances and volumes and to create skeletonized images.an kidney total RNA (20 μg per lane) was fractionated on agarose/formaldehyde
ized overnight and probed with 32P-PRKX (please see Materials and methods for
n adult kidney. PKD: ADPKD kidney. Arrow indicates the 6.4-kb PRKXmRNA;
pression in human kidneys. In situ hybridization with digoxigenin-substituted
was carried out on human kidney sections and visualized by anti-digoxigenin-
ll details). (A and D) Normal human fetal kidney, 12 weeks gestation. (B and E)
be on ADPKD cystic kidney.
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3.1. PRKX mRNA and polycystin-1 protein expression in
human kidneys
The developmental regulation of expression and cellular
localization of PRKX is very similar to that of polycystin-1 in
normal fetal, normal adult and ADPKD kidneys (Fig. 1). Both
are highly expressed in fetal kidneys (A and D) and restricted
mainly to the ureteric bud- derived collecting ducts (gestational
ages 12 to 24 weeks, n=10) while little is seen in normal adult
kidneys (n=10) (B and E). By contrast, PRKX and polycystin-1
expression are seen in ADPKD kidneys (n=10) where they areFig. 3. Co-immunoprecipitation of PRKX and polycystin-1. 800 μg HFCT cell
lysate was immunoprecipitated with 25 μl A/G beads alone (negative control) or
10 μl anti-PRKX antibody plus 25 μl A/G beads. Aliquots were fractionated by
5% SDS/PAGE and then immunoblotted with anti-PRKX (1:500) and anti-
polycystin-1 (1:10,000) antibodies respectively. Lane 1: IP with anti-PRKX plus
A/G beads, Western immunoblot with anti-polycystin-1 (arrow indicates
polycystin-1 band, N430 kDa). Lane 2: IP with A/G beads alone (immunopre-
cipitate negative control). Lane 3: IP with anti-PRKX plus A/G beads; Western
immunoblot with anti-PRKX (arrow indicates PRKX band, 68 kDa).
Fig. 2. (A) Phosphorylation of Polycystin-1 by PRKX. Polycystin-1 immunopre-
cipitated from human fetal collecting tubule (HFCT) cell lysates was
incubated with pFLAG/PRKX fusion protein purified by immunoprecipitation
with anti-FLAG beads. Kinase activity was measured using γ-32P-ATP in the
presence of 8-Br-cAMP (please see Materials and methods for details). The arrow
indicates phosphorylated polycystin-1. Lane 1: HFCTcell lysate incubatedwithout
pFLAG/PRKX. Lane 2: HFCT cell lysate incubated with pFLAG/PRKX. Lane 3:
HFCT cell lysate immunoprecipitated by beads alone and incubated without
pFLAG/PRKX (immunoprecipitation negative control). Lane 4: HFCT cell lysate
immunoprecipitated by polycystin-1 antibody, incubated without pFLAG/PRKX.
Lane 5: HFCTcell lysate immunoprecipitated by polycystin-1 antibody, incubated
with pFLAG/PRKX. (B) Identification of PRKX phosphorylation site on
polycystin-1. Upper panel: His/FLAG/PKD1-CTD fusion protein or 4166 or
4252 site mutated fusion proteins were made in E. coli and purified using a nickel
column. pFLAG/PRKX fusion proteins were obtained from JAR cell lysates
transfected with pFLAG/PRKX by immunoprecipitation using anti-FLAG beads.
In these experiments, the same amounts of His/FLAG/PKD-CTD fusion protein
or of 4166-, or 4252-site mutated fusion proteins were used to incubate with
equal amounts of pFLAG/PRKX fusion protein, respectively. Then equal amounts
of incubation mixtures were loaded for SDS-PAGE followed by autora-
diography. Kinase activity was measured using γ-32P-ATP in the presence or
absence of 8-Br-cAMP (100 μM) or H89 (10 μM) inhibitor. (1) Control without
PRKX transfection. (2) pFLAG/PRKX+His/FLAG/PKD-CTD. (3) pFLAG/
PRKX+His/FLAG/PKD-CTD+cAMP. (4) pFLAG/PRKX+His/FLAG/PKD-
CTD+cAMP+H89. (5) pFLAG/PRKX+4252 PKD mutant. (6) pFLAG/PRKX+
4252 PKD mutant +cAMP. (7) pFLAG/PRKX+4252 PKD mutant+cAMP+H89.
(8) pFLAG/PRKX+4166 PKD mutant. (9) pFLAG/PRKX+4166 PKD mutant+
cAMP. (10) pFLAG/PRKX+4166 PKD mutant+cAMP+H89. Lower panel:
Coomassie blue staining of the gel to show equal loading of pFLAG/PRKX
fusion protein and His/FLAG/PKD-CTD fusion proteins. The molecular weight of
pFLAG/PRKX is 68 kDa and the molecular weight of His/FLAG/PKD-CTD and
its mutants are 32 kDa.restricted to the cyst lining epithelia (C and F). Cell lines
derived from micro-dissected normal human fetal collecting
ducts (HFCT) express high levels of endogenous polycystin-1
[7,19].Fig. 4. Effects of PRKX on ADPKD cell adhesion. NHCT cells and ADPKD
cells were transfected without or with peGFP/PRKX or peGFP/PRKX.ca using
Lipofectamine and then sorted by Fluorescence-Activated Cell Sorting (FACS)
to isolate GFP-positive cells. 2000 GFP+ or control non-transfected cells were
plated per well in 96 well tissue culture plates precoated with type I collagen.
Adherent cells were quantitated by the colorimetric aqueous MTS assay after 4 h
of attachment. Lane 1: NHCT cells without transfection. Lane 2: ADPKD cells
without transfection. Lane 3: ADPKD cells transfected with empty expression
vector. Lane 4: ADPKD cells transfected with peGFP/PRKX. Lane 5: ADPKD
cells transfected with constitutively active peGFP/PRKX.ca.⁎Pb0.01.
Fig. 6. Effects of PKD1 and PRKX on MDCK cell tubulogenesis. MDCK cells,
with or without transfection of various PRKX and PKD1 constructs were sorted by
FACSand 500GFPpositive or negative cellswere plated perwell in collagen type I
gels. After 10 days of culture inDMEM+10%FBS, gelswere fixed and stained for
examination by fluorescence microscopy. (A) MDCK cells without transfection.
(B) Transfected with empty expression vector pEGFP-C3. (C) Transfected with
peGFP/PRKX. (D)Transfected with pMyr-EGFP-PKD1, treated with 25 ng/ml
HGF. (E) Transfectedwith 4252 sitemutant (M4252) of pMyr-EGF-PKD1, treated
with 25 ng/ml HGF. (F)Transfected with 4166 site mutant (M4166) of pMyr-EGF-
PKD1, treated with 25 ng/ml HGF. (G) Co-transfected with peGFP/PRKX plus
pMyr-EGFP-PKD1, treated with 25 ng/ml HGF. (H) Co-transfected with peGFP/
PRKX plus M4252, treated with 25 ng/ml HGF. (I) Co-transfected with peGFP/
PRKXplusM4252, treated with 25 ng/ml HGF. In collagen gel cultures for 7 days.
Rhodamine-phalloidin staining. All cells were pre-sorted for GFP positivity by
FACS prior to use in tubulogenesis assays.
Fig. 5. Effects of PRKX on ADPKD cell migration. NHCT and ADPKD cells
were transfected without and with peGFP/PRKX using Lipofectamine 2000 and
sorted by FACS. 2000 fluorescent calcein-AM labeled GFP+ or control
untransfected cells were placed in each well of 96 well plates and treated with or
without 100 μM8-Br-cAMP or 10 μMH89. Cell migration was quantitated after
4–48 h using a microfluorimetric plate reader (please see Materials and methods
for details). Values are expressed as mean±SEM from 2 independent ex-
periments in triplicate. P values were calculated by t test comparisons between
ADPKD+V versus ADPKD+PRKX. ⁎Pb0.05. (A) Untreated NHCT (blue
line), ADPKD (red line), ADPKD transfected with empty vector (ADPKD+V,
yellow line) and ADPKD transfected with PRKX (ADPKD+PRKX, green
line). (B) Treated with 100 μM 8-Br-cAMP. (C) Treated with 10 μM H89.
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To determine whether polycystin-1 could be a substrate of
PRKX, in vitro phosphorylation analysis was carried out by
incubation ofHFCTpolycystin-1 immunoprecipitateswith PRKX
fusion proteins in the presence of γ32-P-ATP [4] (Fig. 2A). After
establishing that polycystin-1 can be phosphorylated by PRKX
(Fig. 2A, lane 5), mutation analysis was carried out to determine
the specific site at which this occurs. Immunoprecipitated pFLAG/
PRKX was incubated with wild type or mutated PKD1 fusion
proteins and kinase activity determined in the presence of the
activator, 8-Br-cAMP or of the inhibitor, H89. Since human
polycystin-1 contains two RRSSR consensus sequences, sitesS4166 and S4252were selected for pointmutation. Of interest, the
S4252, but not S4166 had previously been shown to be phos-
phorylated by PKA [4,21]. The results (Fig. 2B) show that PRKX
phosphorylates the wildtype polycystin-1 C-terminal (lane 2), that
this is enhanced by 8-Br-cAMP (lane 3) and inhibited by H89
(lane 4).While truncation of polycystin-1 and removal of the PKA
site (S4252) had no effect on this activity (lanes 5–7), mutation of
the S4166 significantly reduced activity (lanes 8–10) implicating
polycystin S4166 as the major C-terminal target for PRKX
phosphorylation.
3.3. Association of PRKX with polycystin-1
To further investigate if PRKX interacts with polycystin-1 in
vivo, co-immunoprecipitation studies were carried out on HFCT
cells that endogenously express both PRKX and polycystin-1
(Fig. 3). PRKX was immunoprecipitated (lane 3) as a 68 kDa
protein, the lower band being thought to be a degradation product
since it was occasionally observed in Western blots using this
commercial polyclonal antibody.Western immunoblot analysis of
the PRKX immunoprecipitates using our C-terminal domain anti-
polycystin-1 antibody [25] showed the presence of polycystin-1
(lane 1, arrow N430 kDa). No polycystin-1 was detected when
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These results suggest that polycystin-1 is associatedwith PRKX in
HFCT.
3.4. PRKX reduces ADPKD cell adhesion and stimulates
ADPKD cell migration
We next sought to determine whether PRKX could modify the
aberrant functions of ADPKD epithelia in vitro. Human ADPKD
epithelia are significantly more adherent to collagen after 4 h of
attachment than age-matched normal human collecting duct cells
and are also significantly less migratory in response to a growth
factor gradient [9,22]. Transfection of ADPKD epithelia with
wild-type peGFP/PRKXor constitutively active peGFP/PRKX.ca
resulted in significant decreases in the adhesion of ADPKD cells,
compared with untransfected cells or ADPKD cells transfected
with empty vector (Fig. 4). In addition, when ADPKD epithelial
cells were transfected with wild-type peGFP/PRKX migration
profiles resembled those of age-matched normal (NHCT) epithelia
(Fig. 5A). This effect was more accentuated in the presence of 8-
Br-cAMP (Fig. 5B) and inhibited by H89 (Fig. 5C).Fig. 7. (Upper panel) Inhibition of ureteric bud branching morphogenesis and glome
3 days and then labeled by anti-WT-1 and anti-Calbindin for visualization of glomeru
Quantitative analysis using IMAGE J software was carried out to compare glomerula
second branch points (bar graphs). The values are mean±SEM. Paired E11.5 fetal kidn
EGFP-PKD1. n=6 paired kidneys.⁎Pb0.01. (Middle panel) Stimulation of ureteric
culture, experimental conditions and quantitative analysis are the same as described i
vector (VVC), (D) VVC-peGFP/PRKX. n=6 paired kidneys.⁎Pb0.01. (Lower p
morphogenesis and glomerular induction by PRKX. The kidney culture, experimen
panel. Paired E11.5 fetal kidneys were injected with (E) Empty viral vector (VVC),
⁎Pb0.01, ⁎⁎Pb0.05.3.5. PRKX abrogates the effect of an inhibitory PKD1-CTD
fusion protein on MDCK cell branching morphogenesis
The MDCK collagen gel assay is a well-established tool to
study MDCK cell branching morphogenesis. In the culture gel,
MDCK cells form cysts consisting of 8–10 cells by day 7 as
shown in the control (Fig. 6A) We have previously demonstrated
that transfection of PRKX intoMDCK cells induces a tubulogenic
response in 3-dimensional collagen gels, even in the absence
of HGF [3] while transduction of the inhibitory VVC-pMyr-
EGFP-PKD1 inhibits branching morphogenesis in the embryonic
mouse kidney [9]. Fig. 6 shows that transfection of pMyr-EGFP-
PKD1 fusion protein did not induce MDCK cell tubulogenesis
even in the presence of HGF (Fig. 6D), while co-transfection
of pMyr-EGFP-PKD1 plus peGFP/PRKX.ca restored tubulogen-
sis (Fig. 6G). Quantitative analysis showed that peGFP/PRKX.ca
co-transfection with pMyr-EGFP-PKD1 resulted in 8.0±0.25
(mean±SEM) branched epithelial structures observed per 10
epithelial structures scored (n=4 sets of observations). Transfec-
tion of the 4166- or 4252-site mutant of pMyr-EGFP-PKD1,
lacking the PRKX major or minor phosphorylation site,rular induction by dominant negative PKD1. Kidney explants were cultured for
li and ureteric bud, respectively and viewed by fluorescent confocal microscopy.
r number, ureteric length, branch points, tips, and outer diameters at the first and
eys were injected on day 0 with: (A) Empty viral vector (VVC). (B) VVC-pMyr-
bud branching morphogenesis and glomerular induction by PRKX. The kidney
n the upper panel. Paired E11.5 fetal kidneys were injected with (C) Empty viral
anel) Rescue of PKD1 dominant negative effects on ureteric bud branching
tal conditions and quantitative analysis are the same as described in the Upper
(F) VVC-pMyr-EGFP-PKD1 plus VVC-peGFP/PRKX.ca. n=6 paired kidneys.
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esis (Fig. 6E and F). Co-transfection of the peGFP/PRKX.ca
togetherwith the 4166- or 4252-sitemutant of pMyr-EGFP-PKD1
did not restore tubulogenesis (Fig. 6H, I). These results suggested
that PRKX can overcome the deficiencies in tubulogenesis
induced by inhibition of polycystin-1 only when both the PRKX
major andminor phosphorylation sites in polycystin-1 are present.
3.6. Microinjection of VVC-peGFP/PRKX.ca rescues the
inhibitory effects of pMyrEGFP-PKD1-CTD
Embryonic mouse kidneys grown in organ culture, recapit-
ulate the epithelial morphogenetic events of early kidney de-
velopment [23,24]. Since polycystin-1 and PRKX are highly
expressed in the ureteric bud, this site was chosen for the mic-
roinjection of lentiviral (VVC) expression constructs of pMyr-
EGFP-PKD1 and/or peGFP/PRKX.ca in embryonic day 11.5
mouse kidneys (Fig. 7). After 3 days of subsequent organ
culture, VVC-pMyr-EGFP-PKD1 transduction alone caused
reductions in ureteric bud elongation and branching as measured
by numbers of branch points and branch tips by comparison to
empty vector injected paired control kidneys. Glomerular num-
bers were also decreased, while ureteric tubular diameters were
increased (Fig. 7, upper panel). The opposite effects were seen
after injection of VVC-peGFP/PRKX.ca alone which led to
increased ureteric bud elongation and branching, increased
glomerular induction and decreased tubular diameters (Fig. 7,
middle panel). Co-transduction by co-microinjection of both
VVC-pMyr-EGFP-PKD1 and VVC-peGFP/PRKX.ca led to the
restoration of normal control levels of ureteric bud elongation
and branching and glomerular induction and significantly
reversed the alterations in tubule dilation (Fig. 7, lower panel).
These results suggest that activated PRKX can rescue the major
inhibitory morphogenetic effects of inhibitory PKD1 mutation
associated with cystic initiation in developing kidneys.
4. Discussion
In the present study, we demonstrated that PRKX is ex-
pressed in the same temporo-spatial pattern as the polycystin-1
protein in the ureteric bud epithelial of normal developing
kidneys [6,7]. We also demonstrated that PRKX associates with
polycystin-1 in human fetal kidney collecting tubule (HFCT)
epithelial cells and can phosphorylate the polycystin-1 protein.
These results suggest that PRKX may interact with polycystin-1
and regulate polycystin-1 functions in renal epithelial cells in
vivo. During development of the metanephric kidney, the ure-
teric bud undergoes branching morphogenesis that involves
epithelial cell adhesive interactions with the extracellular ma-
trix, migration, branching, elongation and tubule diameter re-
gulation and epithelial differentiation. During this process,
polycystin-1 shows a punctate basal membrane distribution
pattern and forms multiprotein complexes with integrins and
component proteins of the focal adhesion complex including
paxillin, talin, tensin, focal adhesion kinase, c-src and p130cas
[25,26]. Recent studies have demonstrated a direct role for
polycystin-1 in the regulation of the ordered control of epithelialcell adhesion, migration, elongation, branching morphogenesis
and volume regulation necessary for normal renal development
[9]. PRKX, a cAMP-dependent CREB kinase, also regulates
similar properties, stimulating renal epithelia cell migration and
branching morphogenesis [3]. Therefore, we reasoned that
PRKX might act as a polycystin-1 kinase and modulate its
functions through phosphorylation of polycystin-1 at its intra-
cellular C terminal domain.
Sequence analysis identified 4 tyrosine residues and 2RRSSR
consensus sequences as putative target sites for phosphorylation
by kinases in of the intracellular portion of polycystin-1 and
functional analysis has confirmed that S4252 is a phosphoryla-
tion site for PKA, Y4127 for focal adhesion kinase (FAK) and
Y4237 for c-src [3,4,21]. Our current observation that PRKX
phosphorylates polycystin-1 at S4166, rather than at S4252 (the
only phosphorylation site for PKA) suggests that PRKX and
PKA could exert distinct effects on polycystin-1. Indeed, our
previous studies had demonstrated clear functional differences
between PRKX and PKA with regard to renal epithelial cell
function since while PRKX stimulates cell migration, and tu-
bulogenesis PKA has no effects on those properties [3,36].
Human ADPKD epithelia with mutant PKD1 have increased
adhesion and reduced migratory capacity and inhibition of
PKD1 disrupts ureteric bud branching morphogenesis leading to
cystic dilation [9]. Since over-expression of PRKX had been
shown to increase branching morphogenesis, we reasoned that it
might counteract the effects of PKD1 inhibition via modulation
of polycystin-1. Using transfection strategies, PRKXwas shown
to significantly decrease the adhesion and increase the migration
of ADPKD cells, retuning them to the levels seen in normal age-
matched control cells. PRKX was also shown to stimulate
MDCK cell branchingmorphogenesis and to abrogate the effects
of an inhibitory pMyr-PKD1-CTD fusion protein onMDCK cell
branching morphogenesis in 3-dimensional collagen gels. Most
importantly, the co-injection and transduction of PRKX into the
ureteric buds of E11.5 mouse embryonic kidneys in ex vivo
organ culture led to an almost complete rescue of the branching
morphogenesis and cystic dilation defect elicited by injection of
inhibitory pMyr-EGFP-PKD1. Taken together these results
suggest that PRKX can reverse the abnormalities in epithelial
adhesion, migration and morphogenesis associated with PKD1
inhibition and cyst formation in ADPKD. There are several
potential mechanisms whereby PRKX might counteract the
effects of PKD1 dysfunction. Firstly, since human ADPKD
patients are heterozygous for a single PKD1 mutation and im-
munoreactive polycystin-1 protein is seen inmany cyst epithelial
cells in human ADPKD kidneys, PRKX may be able to counter-
act the deleterious effects of haplo-insufficiency by interacting
with protein encoded by the normal allele. Secondly, PRKX
might act in a dominant negative fashion by competing with
aberrant polycystin-1, thus blocking the deleterious effects of
the mutant protein. A third potential mechanism would be that
PRKX interacts with other members of the polycystin-1–
multiprotein complex to abrogate aberrant function. Consistent
with this possibility, PRKX contains a proline-rich (WW) bind-
ing site and in vitro binding assays has been shown capable of
strong interactions with PIN-1, BAG-3 and MAGI-1 shown
8 X. Li et al. / Biochimica et Biophysica Acta 1782 (2008) 1–9to play a role in regulation of cell proliferation and differenti-
ation. Further in vitro and in vivo studies in PKD1 null homo-
zygous and heterozygous mice are in progress to address these
alternatives.
Mutation of PKD1 in ADPKD leads to functional insuffi-
ciency associated with tubular cystic dilation. Severe inhibition
of PKD1 during renal development by injection of inactivating
pMyr-EGFP-PKD1 viral expression constructs or by PKD1
mutation inADPKD, disrupts and retards ureteric bud branching,
reduces total glomerular induction and leads to tubular dilations
[9]. PRKX is the first endogenous protein demonstrated to
reverse the effects of PKD1 mutation and points to the potential
importance of phosphorylation of the intracellular C-terminus
of polycystin-1 by this kinase in mitigating the progressive
renal dysfunction seen in this monogenetic disease. 85% of
ADPKD is caused by mutations in PKD1 and 15% by mutations
in PKD2. Recent studies suggest that the intracellular C-terminal
of the PKD2-encoded polycystin-2 also contains putative serine
target sites for phosphorylation and that inhibition of PKD2
disrupts renal epithelial tubulogenesis [38]. Polycystin-1 and
polycystin-2 have been shown to interact in vitro and have been
proposed to form functional complexes in vivo. Although it
remains to be determined whether PRKX can phosphorylate
polycystin-2, it is likely that it is capable of regulating polycystin-
2 function either directly or by virtue of its interactions with
polycystin-1 in the polycystin1/2 complex. Since over-expression
of PRKX has been shown to be efficient at restoring normal
polycystin function in vitro and ex vivo, this presents the pos-
sibility that PRKX therapy might be effective with regard to
prevention and/or retardation of cystic development.
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